Don B Sanders1, Julia Emerson2, Clement L Ren3, Michael S Schechter4, Ronald L Gibson2, Wayne Morgan5, Margaret Rosenfeld2. 1. 1 Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. 2. 2 Department of Pediatrics, Seattle Children's Hospital and University of Washington School of Medicine, Seattle, Washington. 3. 3 Department of Pediatrics, University of Rochester Medical Center, Rochester, New York. 4. 4 Department of Pediatrics, Virginia Commonwealth University and Children's Hospital of Richmond, Richmond, Virginia; and. 5. 5 Department of Pediatrics, University of Arizona, Tucson, Arizona.
Abstract
RATIONALE: There are limited objective measures of the severity of lung disease before children are able to routinely perform spirometry, generally at age 6 years. Identifying risk factors for reduced lung function at age 6 provides opportunities to intervene and slow the progression of cystic fibrosis (CF) lung disease. OBJECTIVES: To evaluate early childhood predictors of lung function at age 6-7 in a large U.S. CF cohort in the current era of widespread early eradication therapy for Pseudomonas aeruginosa (P. aeruginosa). METHODS:Participants were children with CF enrolled before age 4 in the Early Pseudomonas Infection Control (EPIC) Observational Study, a multicenter, longitudinal study that enrolled P. aeruginosa-negative children not exceeding 12 years of age. Linear regression was used to estimate the association between potential early childhood risk factors and the best FEV1% predicted at age 6-7 years. MEASUREMENTS AND MAIN RESULTS: Four hundred and eighty-four children (of 1,797 enrolled in the EPIC Observational Study) met the eligibility criteria for this analysis. Mean (SD) age at enrollment was 2.0 (1.3) years. In a multivariable model adjusted for age at enrollment, the following risk factors were significantly associated with lower mean (95% confidence interval) FEV1% predicted at age 6-7: weight percentile less than 10% during the year of enrollment (-5.3 [-9.1, -1.5]), P. aeruginosa positive during the year of enrollment (-2.8 [-5.7, 0.0]), crackles or wheeze during the year of enrollment (-5.7 [-9.4, -1.9]), mother's education of high school or less (-4.2 [-7.3, -1.2]), and mother smoked during pregnancy (-4.4 [-8.8, 0.1]). CONCLUSIONS: In this large U.S. cohort, we identified several early childhood risk factors for lower FEV1 at age 6-7 years, most of which are modifiable. Clinical trial registered with www.clinicaltrials.gov (NCT00097773).
RCT Entities:
RATIONALE: There are limited objective measures of the severity of lung disease before children are able to routinely perform spirometry, generally at age 6 years. Identifying risk factors for reduced lung function at age 6 provides opportunities to intervene and slow the progression of cystic fibrosis (CF) lung disease. OBJECTIVES: To evaluate early childhood predictors of lung function at age 6-7 in a large U.S. CF cohort in the current era of widespread early eradication therapy for Pseudomonas aeruginosa (P. aeruginosa). METHODS:Participants were children with CF enrolled before age 4 in the Early Pseudomonas Infection Control (EPIC) Observational Study, a multicenter, longitudinal study that enrolled P. aeruginosa-negative children not exceeding 12 years of age. Linear regression was used to estimate the association between potential early childhood risk factors and the best FEV1% predicted at age 6-7 years. MEASUREMENTS AND MAIN RESULTS: Four hundred and eighty-four children (of 1,797 enrolled in the EPIC Observational Study) met the eligibility criteria for this analysis. Mean (SD) age at enrollment was 2.0 (1.3) years. In a multivariable model adjusted for age at enrollment, the following risk factors were significantly associated with lower mean (95% confidence interval) FEV1% predicted at age 6-7: weight percentile less than 10% during the year of enrollment (-5.3 [-9.1, -1.5]), P. aeruginosa positive during the year of enrollment (-2.8 [-5.7, 0.0]), crackles or wheeze during the year of enrollment (-5.7 [-9.4, -1.9]), mother's education of high school or less (-4.2 [-7.3, -1.2]), and mother smoked during pregnancy (-4.4 [-8.8, 0.1]). CONCLUSIONS: In this large U.S. cohort, we identified several early childhood risk factors for lower FEV1 at age 6-7 years, most of which are modifiable. Clinical trial registered with www.clinicaltrials.gov (NCT00097773).
Authors: Michael W Konstan; Wayne J Morgan; Steven M Butler; David J Pasta; Marcia L Craib; Stefanie J Silva; Dennis C Stokes; Mary Ellen B Wohl; Jeffrey S Wagener; Warren E Regelmann; Charles A Johnson Journal: J Pediatr Date: 2007-06-22 Impact factor: 4.406
Authors: R T Stein; C J Holberg; D Sherrill; A L Wright; W J Morgan; L Taussig; F D Martinez Journal: Am J Epidemiol Date: 1999-06-01 Impact factor: 4.897
Authors: Zhanhai Li; Michael R Kosorok; Philip M Farrell; Anita Laxova; Susan E H West; Christopher G Green; Jannette Collins; Michael J Rock; Mark L Splaingard Journal: JAMA Date: 2005-02-02 Impact factor: 56.272
Authors: Robert S Tepper; Tamica Williams-Nkomo; Tanya Martinez; Jeff Kisling; Cathy Coates; Joanne Daggy Journal: Am J Respir Crit Care Med Date: 2004-10-22 Impact factor: 21.405
Authors: Michael S Schechter; Susanna A McColley; Stefanie Silva; Tmirah Haselkorn; Michael W Konstan; Jeffrey S Wagener Journal: J Pediatr Date: 2009-07-16 Impact factor: 4.406
Authors: Alexandra L Quittner; Michael S Schechter; Lawrence Rasouliyan; Tmirah Haselkorn; David J Pasta; Jeffrey S Wagener Journal: Chest Date: 2009-10-09 Impact factor: 9.410
Authors: Philip M Farrell; Beryl J Rosenstein; Terry B White; Frank J Accurso; Carlo Castellani; Garry R Cutting; Peter R Durie; Vicky A Legrys; John Massie; Richard B Parad; Michael J Rock; Preston W Campbell Journal: J Pediatr Date: 2008-08 Impact factor: 4.406
Authors: Thida Ong; Michael Schechter; Jing Yang; Limin Peng; Julia Emerson; Ronald L Gibson; Wayne Morgan; Margaret Rosenfeld Journal: Pediatrics Date: 2017-01-16 Impact factor: 7.124
Authors: Gabriela R Oates; William T Harris; Hector H Gutierrez; Cathy Mims; Sarah B Rutland; Corilyn Ott; Soumya J Niranjan; Isabel C Scarinci; Susan C Walley Journal: Pediatr Pulmonol Date: 2020-06-08
Authors: Gabriela R Oates; Elizabeth Baker; Steven M Rowe; Hector H Gutierrez; Michael S Schechter; Wayne Morgan; William T Harris Journal: J Cyst Fibros Date: 2020-02-17 Impact factor: 5.482
Authors: Scott C Bell; Marcus A Mall; Hector Gutierrez; Milan Macek; Susan Madge; Jane C Davies; Pierre-Régis Burgel; Elizabeth Tullis; Claudio Castaños; Carlo Castellani; Catherine A Byrnes; Fiona Cathcart; Sanjay H Chotirmall; Rebecca Cosgriff; Irmgard Eichler; Isabelle Fajac; Christopher H Goss; Pavel Drevinek; Philip M Farrell; Anna M Gravelle; Trudy Havermans; Nicole Mayer-Hamblett; Nataliya Kashirskaya; Eitan Kerem; Joseph L Mathew; Edward F McKone; Lutz Naehrlich; Samya Z Nasr; Gabriela R Oates; Ciaran O'Neill; Ulrike Pypops; Karen S Raraigh; Steven M Rowe; Kevin W Southern; Sheila Sivam; Anne L Stephenson; Marco Zampoli; Felix Ratjen Journal: Lancet Respir Med Date: 2019-09-27 Impact factor: 30.700
Authors: Rhonda Szczesniak; Jessica L Rice; Cole Brokamp; Patrick Ryan; Teresa Pestian; Yizhao Ni; Eleni-Rosalina Andrinopoulou; Ruth H Keogh; Emrah Gecili; Rui Huang; John P Clancy; Joseph M Collaco Journal: Expert Rev Respir Med Date: 2020-04-26 Impact factor: 3.772
Authors: Gabriela R Oates; Elizabeth Baker; Joseph M Collaco; Steven M Rowe; Sarah B Rutland; Christopher M Fowler; William T Harris Journal: J Cyst Fibros Date: 2021-07-17 Impact factor: 5.527
Authors: Nicole Mayer-Hamblett; George Retsch-Bogart; Margaret Kloster; Frank Accurso; Margaret Rosenfeld; Gary Albers; Philip Black; Perry Brown; AnneMarie Cairns; Stephanie D Davis; Gavin R Graff; Gwendolyn S Kerby; David Orenstein; Rachael Buckingham; Bonnie W Ramsey Journal: Am J Respir Crit Care Med Date: 2018-11-01 Impact factor: 30.528
Authors: Elizabeth Baker; William T Harris; Steven M Rowe; Sarah B Rutland; Gabriela R Oates Journal: J Cyst Fibros Date: 2020-10-03 Impact factor: 5.527